Why Did Tonix Pharmaceuticals (TNXP) Soar 12.64%? FDA Decision Looms

On August 15, 2025, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant surge in its stock price, rising by 12.64% in pre-market trading.

Investor optimism surrounding Tonix Pharmaceuticals Holding Corp. (TNXP) has been driven by the anticipation of a key FDA decision regarding Tonmya, a drug developed by the company. This optimism has led to a substantial increase in the stock's value, with shares surging by 62% since the buy call was made.

Additionally, Tonix Pharmaceuticals has reported its quarterly earnings, which, while missing expectations by $0.76 EPS, have not deterred investor enthusiasm. The company's financial outlook remains a focal point for investors, with expectations that the company will have sufficient cash to fund operations into the third quarter of 2026.

The upcoming FDA decision on Tonmya is seen as a critical catalyst for the stock, with investors closely monitoring the situation. This catalyst, along with the company's financial stability, has contributed to the recent gains in TNXP's stock price.